Other IL-23 UC options, which include Eli Lilly’s Omvoh, the first in the drug category to hit the market in 2023, and AbbVie’s Skyrizi, approved for UC and Crohn’s disease in June ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback